PTGX (Protagonist Therapeutics) Short-Term Debt to Capital
Protagonist Therapeutics (PTGX) generates revenue through interim tranches from industry behemoths, which ensures capital purity and reduces trial expenses. Current cash flow relies on the momentum of past achievements rather than sales, with the metric standing at 0.00. The price action of the securities is presented below. The business is based on the development of oral peptide drug formulations for the therapy of gastrointestinal and blood pathologies.
Analytical breakdowns for Protagonist Therapeutics
- stock quotes and analyst forecast:
- business market valuation indicators:
- book capitalization information:
- company liabilities and liquidity data:
Total Debt to Capital Protagonist Therapeutics|PTGX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Protagonist|PTGX - Aggregate Debt Obligations|Debts to Book Capitalization Protagonist Therapeutics, Inc.|PTGX - Long-Term Debt Volume|Company Short-Term Debt Protagonist Therapeutics|Quick Liquidity protagonist-inc.com
- company profitability and valuation multiples indicators:
Fundamental valuation:Protagonist Therapeutics Inc
This indicator measures the proportion of liabilities maturing within one year relative to equity, determining the company's dependence on operational refinancing and its vulnerability to market shocks. The current value of 0.00 in the historical trend of short-term loans to equity reflects the financial leverage of Protagonist Therapeutics (PTGX), which, during the development stage of proprietary peptides, is critically dependent on external financing until the commercial potential of the drugs is realized.
Main competitors
Short-Term Debt to Capital ARGX|BNTX (BioNTech Pharma) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ABVX (Abivax Pharma)|Short-Term Debt to Capital admabiologics.com ADMA|IMVT - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital KNSA (Kiniksa Pharmaceuticals, Ltd.)|Grifols Group (GRFS) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Adaptive Biotechnologies Inc.|CLDX (Celldex Therapeutics) - Short-Term Debt to Capital|Short-Term Debt to Capital auriniapharma.com|Short-Term Debt to Equity Ratio BCRX (BioCryst Pharmaceuticals)|VERA (Vera Therapeutics Inc) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital DNTH (Dianthus Pharma)|Short-Term Debt to Capital Coefficient Pharvaris Pharma (PHVS)|ABCL - Short-Term Debt to Equity|tourmalinebio.com (TRML) - Short-Term Debt to Equity Ratio|Precigen (PGEN) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Pharming Group NV|Short-Term Debt to Equity Ratio NKTR|Short-Term Debt to Capital Upstream Pharma|Short-Term Debt to Equity Zenas Biopharma Inc (ZBIO)|immunome.com - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital GOSS (Gossamer Bio)|KalVista Pharma (KALV) - Current Liabilities to Capital|SEPN - Short-Term Debt to Equity|Current Liabilities to Equity PVLA|Savara Inc. (SVRA) - Short-Term Debt to Equity|rigel.com - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity AnaptysBio|Current Liabilities to Capital Astria Therapeutics Inc ATXS|Short-Term Debt to Equity Ratio ENGN (enGene Bio)|Short-Term Loans to Capital Ratio RAPT|Short-Term Debt to Capital JBIO (Aerovate Therapeutics)|Short-Term Debt to Capital aclaristx.com ACRS|Kyverna Therapeutics, Inc. - Short-Term Debt to Capital|Short-Term Indebtedness to Equity Tiziana Life Sciences Ltd. (TLSA)|Cabaletta Bio, Inc (CABA) - Short-Term Debt to Equity|Current Liabilities to Capital Ventyx Biosciences, Inc (VTYX)|Short-Term Debt to Equity Theratechnologies Inc.|Short-Term Debt to Capital Ratio AVTX (avalotx.com)|Short-Term Debt to Capital ELDN|Short-Term Debt to Capital Coefficient Agenus, Inc.|Short-Term Debt to Equity Climb Bio, Inc. CLYM|Short-Term Debt to Capital Coefficient zurabio.com (ZURA)|ATYR: Short-Term Debt to Equity Ratio|Adagene - Short-Term Loans to Capital Ratio|IMA (ikenaoncology.com) - Short-Term Debt to Equity Ratio|Shattuck Labs - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio EQ|CNTB (Connect Pharma) - Short-Term Loans to Capital Ratio|Short-Term Debt to Capital IMUX|ATRA (atarabio.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital IFRX (InflaRx)|X4 Pharmaceuticals Inc. (XFOR) - Current Liabilities to Capital|ACET - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital CELU (Celularity Inc.)|INMB: Short-Term Debt to Capital|barinthusbio.com (BRNS) - Short-Term Debt to Capital|Short-Term Debt to Equity Kezar Life Sciences, Inc.|SAB Biotherapeutics Inc. - Current Liabilities to Equity|Short-Term Debt to Capital AKTX|ENLV - Current Liabilities to Capital|Q32 Bio - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital geovax.com GOVX|EDSA: Short-Term Debt to Equity Ratio|iBio Inc - Short-Term Loans to Capital Ratio|CARM: Short-Term Debt to Capital|XTLB - Short-Term Debt to Capital Coefficient|BOLT (Bolt Biotherapeutics Inc.) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio HCW Biologics Inc (HCWB)|Short-Term Debt to Equity Aptevo Therapeutics (APVO)|Short-Term Debt to Capital Coefficient aimimmuno.com|Short-Term Debt to Equity Aditxt, Inc. ADTX|GRI (GRI Bio Corporation) - Current Liabilities to Equity|XRTX: Short-Term Debt to Equity Ratio|reshapelifesciences.com - Short-Term Loans to Capital Ratio|REVB: Short-Term Debt to Capital|Short-Term Indebtedness to Equity Indaptus Therapeutics Inc INDP|Short-Term Debt to Equity Ratio SCNI|Short-Term Debt to Capital Ratio CALI (CalciMedica Corp)|Short-Term Debt to Equity Affimed (AFMD)|ALLK: Current Liabilities to Equity|Short-Term Debt to Capital HOOK (HOOKIPA Pharma)|Ratio of Short-Term Indebtedness to Capital IGMS|iTeos - Short-Term Debt to Capital|OCEA - Short-Term Debt to Capital|TC Biopharm (TCBP) - Short-Term Debt to Equity|thirdharmonicbio.com - Ratio of Short-Term Indebtedness to Capital